miR-10b靶向TGFBR1/SMAD3通路对特发性矮小症的软骨细胞增殖、肥大的影响机制

doi:10.11958/20230659

天津医药 ›› 2024, Vol. 52 ›› Issue (2): 124-128.doi: 10.11958/20230659

miR-10b靶向TGFBR1/SMAD3通路对特发性矮小症的软骨细胞增殖、肥大的影响机制

胡娜(), 李正宇, 叶春风, 吴英, 姚庆, 黄世祥, 李文, 朱海琴^△()

南昌大学第二附属医院儿科（邮编330038）

收稿日期:2023-04-30 修回日期:2023-09-05 出版日期:2024-02-15 发布日期:2024-01-26
通讯作者: ^△ E-mail：904668463@qq.com
作者简介:胡娜（1982），女，主治医师，主要从事儿童生长发育方面研究。E-mail:hunajx@163.com
基金资助:
江西省卫生健康委科技计划项目(20204274)

The mechanism of miR-10b targeting TGFBR1/SMAD3 pathway on chondrocyte proliferation and hypertrophy in idiopathic short stature

HU Na(), LI Zhengyu, YE Chunfeng, WU Ying, YAO Qing, HUANG Shixiang, LI Wen, ZHU Haiqin^△()

Department of Pediatrics, the Second Affiliated Hospital of Nanchang University, Nanchang 330038, China

Received:2023-04-30 Revised:2023-09-05 Published:2024-02-15 Online:2024-01-26
Contact: ^△ E-mail：904668463@qq.com

胡娜, 李正宇, 叶春风, 吴英, 姚庆, 黄世祥, 李文, 朱海琴. miR-10b靶向TGFBR1/SMAD3通路对特发性矮小症的软骨细胞增殖、肥大的影响机制[J]. 天津医药, 2024, 52(2): 124-128.

HU Na, LI Zhengyu, YE Chunfeng, WU Ying, YAO Qing, HUANG Shixiang, LI Wen, ZHU Haiqin. The mechanism of miR-10b targeting TGFBR1/SMAD3 pathway on chondrocyte proliferation and hypertrophy in idiopathic short stature[J]. Tianjin Medical Journal, 2024, 52(2): 124-128.

摘要/Abstract

摘要：

目的研究miR-10b对特发性矮小症（ISS）的影响及作用机制。方法收集ISS患儿（ISS组）和体检健康儿童（健康对照组）各54例，qPCR检验血清miR-10b表达量，分析ISS组患儿血清miR-10b表达与患儿临床资料的关系。采用miR-10b inhibitor、si-TGFBR1及各自阴性对照转染C28/I2细胞，利用CCK-8实验检测C28/I2细胞增殖能力，Western blot检测侏儒相关转录因子2（RUNX2）、X型胶原α1链（COL10A1）、转化生长因子β受体1（TGFBR1）、SMAD3、pSMAD3蛋白表达量。在StarBase数据库筛选miR-10b靶点，利用双萤光素酶报告基因实验验证miR-10b与TGFBR1的靶向关系。结果 ISS组血清miR-10b表达量高于健康对照组，且miR-10b表达越高，患儿的身高、IGF-1、骨特异性碱性磷酸酶的下降越明显（P<0.05）。与NC组相比，miR-10b inhibitor组细胞增殖能力升高，RUNX2、COL10A1、TGFBR1、pSMAD3蛋白表达上调（P<0.05）；StarBase数据库提示miR-10b存在TGFBR1的结合位点，双萤光素酶报告基因实验证实两者结合。与si-NC相比，si-TGFBR1组TGFBR1表达量下调，细胞增殖能力下降（P<0.05）。结论 miR-10b通过靶向TGFBR1/SMAD3通路在特发性矮小症中抑制软骨细胞的增殖、肥大。

关键词: 特发性矮小症, 受体, 转化生长因子βⅠ型, miR-10b, Smad3蛋白质

Abstract:

Objective To investigate the effect and mechanism of microRNA-10b (miR-10b) on idiopathic short stature (ISS). Methods A total of 54 children with ISS and 54 healthy children were collected. The serum expression of miR-10b was detected by RT-qPCR, and the relationship between serum miR-10b expression and clinical data of children with ISS was analyzed. miR-10b inhibitor, si-TGFBR1 and their negative control transfection C28/I2 cells were used. CCK-8 experimental detection was used to detect C28/I2 cell proliferation. Western blot assay was used to detect gnome related transcription factor 2 (RUNX2), collagen type X alpha 1 chain (COL10A1), transforming growth factor beta receptor 1 (TGFBR1), SMAD3 and pSMAD3 protein expression. The target of miR-10b was screened in StarBase database, and the targeting relationship between miR-10b and TGFBR1 was verified by dual luciferase reporter gene assay. Results The serum expression of miR-10b was higher in the ISS group than that of the healthy control group, and the higher the miR-10b expression, the more obvious the decrease of child height, IGF-1 and alkaline phosphatase (P<0.05). Compared with the NC group, the cell proliferation ability and RUNX2, COL10A1, TGFBR1, and pSMAD3 protein expression were up-regulated in the miR-10b inhibitor group (P<0.05). StarBase database suggested that miR-10b had a binding site of TGFBR1, and dual luciferase reporter gene assay confirmed that TGFBR1 interacted with miR-10b (P<0.05). Compared with the si-NC group, the expression of TGFBR1 was down-regulated and the cell proliferation ability was decreased in the si-TGFBR1 group (P<0.05). Conclusion miR-10b inhibits chondrocyte proliferation and hypertrophy in idiopathic short stature by targeting TGFBR1/SMAD3 pathway.

Key words: idiopathic short stature, receptor, transforming growth factor-beta type Ⅰ, miR-10b, Smad3 protein

中图分类号:

R752.8

图/表 7

参考文献 21

[1]	LIU X, DU Z, YI X, et al. Circular RNA circANAPC2 mediates the impairment of endochondral ossification by miR-874-3p/SMAD3 signalling pathway in idiopathic short stature[J]. J Cell Mol Med, 2021, 25(7):3408-3426. doi:10.1111/jcmm.16419.
[2]	HILL M, TRAN N. MiRNA interplay:mechanisms and consequences in cancer[J]. Dis Model Mech, 2021, 14(4):dmm047662. doi:10.1242/dmm.047662.
[3]	DIENER C, KELLER A, MEESE E. Emerging concepts of miRNA therapeutics:from cells to clinic[J]. Trends Genet, 2022, 38(6):613-626. doi:10.1016/j.tig.2022.02.006.
[4]	PENG D, FU M, WANG M, et al. Targeting TGF-β signal transduction for fibrosis and cancer therapy[J]. Mol Cancer, 2022, 21(1):104. doi:10.1186/s12943-022-01569-x.
[5]	SAVAGE M O, STORR H L. GH resistrnce is a component of idiopathic short stature:implications for rhGH therapy[J]. Front Endocrinol(Lausanne), 2021, 12:781044. doi:10.3389/fendo.2021.781044.
[6]	VYAS V, MENON R K. Management of short stature:use of growth hormone in GH-Deficient and non-GH-Deficient conditions[J]. Indian J Pediatr, 2021, 88(12):1203-1208. doi:10.1007/s12098-021-03892-5.
[7]	WU Z, YUAN J, LI J, et al. Hsa_circ_0008870 suppresses bone formation of growth plate through inhibition of miR-185-3p/ MAPK1 axis in idiopathic short stature[J]. Front Bioeng Biotechnol, 2022, 10:1022830. doi:10.3389/fbioe.2022.1022830.
[8]	DU X, ZHANG J, WANG J, et al. Role of miRNA in lung cancer-potential biomarkers and therapies[J]. Curr Pharm Des, 2018, 23(39):5997-6010. doi:10.2174/1381612823666170714150118.
[9]	PEI C, GONG X, ZHANG Y. LncRNA MALAT-1 promotes growth and metastasis of epithelial ovarian cancer via sponging microRNA-22[J]. Am J Transl Res, 2020, 12(11):6977-6987.
[10]	AKHTARKHAVARI T, BAHRAMI A R, MATIN M M. Downregulation of miR-21 as a promising strategy to overcome drug resistance in cancer[J]. Eur J Pharmacol, 2022, 932:175233. doi:10.1016/j.ejphar.2022.175233.
[11]	ZHANG Y, WANG F, CHEN G, et al. LncRNA MALAT1 promotes osteoarthritis by modulating miR-150-5p/AKT3 axis[J]. Cell Biosci, 2019, 9:54. doi:10.1186/s13578-019-0302-2.
[12]	IAQUINTA M R, LANZILLOTTI C, MAZZIOTTA C, et al. The role of microRNAs in the osteogenic and chondrogenic differentiation of mesenchymal stem cells and bone pathologies[J]. Theranostics, 2021, 11(13):6573-6591. doi:10.7150/thno.55664.
[13]	张瑞欣, 董语迪, 肖建辉. lncRNA调控间充质干细胞向成骨细胞分化的研究进展[J]. 天津医药, 2021, 49(6):662-667.
	ZHANG R X, DONG Y D, XIAO J H. Research progress of lncRNA regulating the differentiation of mesenchymalstem cells into osteoblasts[J]. Tianjin Med J, 2021, 49(6):662-667. doi:10.11958/20203229.
[14]	ZHANG F Y, ZHEN Y F, GUO Z X, et al. miR-143 is implicated in growth plate injury by targeting IHH in precartilaginous stem cells[J]. Int J Med Sci, 2021, 18(9):1999-2007. doi:10.7150/ijms.46474.
[15]	RAVAL A, JOSHI J, SHAH F. Significance of metastamiR-10b in breast cancer therapeutics[J]. J Egypt Natl Canc Inst, 2022, 34(1):19. doi:10.1186/s43046-022-00120-9.
[16]	LIU F, SHI Y, LIU Z, et al. The emerging role of miR-10 family in gastric cancer[J]. Cell Cycle, 2021, 20(15):1468-1476. doi:10.1080/15384101.2021.1949840.
[17]	GE G, YANG D, TAN Y, et al. miR-10b-5p regulates C2C12 myoblasts proliferation and differentiation[J]. Biosci Biotechnol Biochem, 2019, 83(2):291-299. doi:10.1080/09168451.2018.1533805.
[18]	KOMORI T. Runx2,an inducer of osteoblast and chondrocyte differentiation[J]. Histochem Cell Biol, 2018, 149(4):313-323. doi:10.1007/s00418-018-1640-6.
[19]	CHEN J, CHEN F, BIAN H, et al. Hypertrophic chondrocyte-specific Col10a1 controlling elements in Cre recombinase transgenic studies[J]. Am J Transl Res, 2019, 11(10):6672-6679.
[20]	HU H H, CHEN D Q, WANG Y N, et al. New insights into TGF-β/Smad signaling in tissue fibrosis[J]. Chem Biol Interact, 2018, 292:76-83. doi:10.1016/j.cbi.2018.07.008.
[21]	XIAO L, XU S, XU Y, et al. TGF-β/SMAD signaling inhibits intermittent cyclic mechanical tension-induced degeneration of endplate chondrocytes by regulating the miR-455-5p/RUNX2 axis[J]. J Cell Biochem, 2018, 119(12):10415-10425. doi:10.1002/jcb.27391.

基因名称	引物序列（5′→3′）	产物大小/bp
GAPDH	上游：TGCTGGTGCTGAGTATGTCG	85
GAPDH	下游：GCATGTCAGATCCACAACGG	85
U6	上游：CTCGCTTCGGCAGCACA	105
U6	下游：AACGCTTCACGAATTTGCGT	105
miR-10b	上游：AACGCTTCACGAATTTGCGT	78
miR-10b	下游：GTGCTACCCTGTAGAAC	78
TGFBR1	上游：GTAGCTCTGATGAGTGCAATGAC	120
TGFBR1	下游：CAGATATGGCAACTCCCAGTG	120
SMAD3	上游：AGTGGAGCTGACACGGAGAC	135
SMAD3	下游：AGCGAACTCCTGGTTGTTGA	135

基因名称	引物序列（5′→3′）	产物大小/bp
GAPDH	上游：TGCTGGTGCTGAGTATGTCG	85
GAPDH	下游：GCATGTCAGATCCACAACGG	85
U6	上游：CTCGCTTCGGCAGCACA	105
U6	下游：AACGCTTCACGAATTTGCGT	105
miR-10b	上游：AACGCTTCACGAATTTGCGT	78
miR-10b	下游：GTGCTACCCTGTAGAAC	78
TGFBR1	上游：GTAGCTCTGATGAGTGCAATGAC	120
TGFBR1	下游：CAGATATGGCAACTCCCAGTG	120
SMAD3	上游：AGTGGAGCTGACACGGAGAC	135
SMAD3	下游：AGCGAACTCCTGGTTGTTGA	135

组别		身高/cm		体质量/kg
低表达组		128.6±11.46		23.61±6.15
高表达组		121.1±12.34		21.43±5.23
t		2.314^＊		1.403
组别	BMI/（kg/m²）		IGF-1/（μg/L）		BAP/（U/L）
低表达组	17.31±1.82		241.51±23.56		122.43±22.21
高表达组	16.25±2.06		221.34±32.43		110.39±21.51
t	0.995		2.615^＊		2.023^＊

组别		身高/cm		体质量/kg
低表达组		128.6±11.46		23.61±6.15
高表达组		121.1±12.34		21.43±5.23
t		2.314^＊		1.403
组别	BMI/（kg/m²）		IGF-1/（μg/L）		BAP/（U/L）
低表达组	17.31±1.82		241.51±23.56		122.43±22.21
高表达组	16.25±2.06		221.34±32.43		110.39±21.51
t	0.995		2.615^＊		2.023^＊

组别	miR-10b	细胞增殖活力（OD₄₅₀）
组别	miR-10b	0 h	24 h	48 h	72 h
NC组	1.03±0.12	0.15±0.07	0.41±0.08	0.85±0.12	1.12±0.14
miR-10b inhibitor组	0.23±0.11	0.16±0.05	0.55±0.05	1.21±0.11	1.72±0.12
t	8.512^＊＊	0.201	0.439	3.380^＊	5.636^＊＊

miR-10b靶向TGFBR1/SMAD3通路对特发性矮小症的软骨细胞增殖、肥大的影响机制

The mechanism of miR-10b targeting TGFBR1/SMAD3 pathway on chondrocyte proliferation and hypertrophy in idiopathic short stature

引用本文

RichHTML

PDF (PC)

可视化

摘要/Abstract

使用本文

图/表 7

参考文献 21

相关文章 15

编辑推荐

Metrics

本文评价

[1]	吴杰, 姬冰瑞, 郭瑞霞. 血清PDGF与子宫下段肌壁厚度对瘢痕子宫再次妊娠分娩结局的预测价值[J]. 天津医药, 2026, 54(7): 760-764.
[2]	刘甚红, 马媛媛, 张丽梅. IgE高亲和力受体结合NPC2对DNP-BSA诱导的肥大细胞脱颗粒和组胺释放的机制探讨[J]. 天津医药, 2026, 54(5): 455-461.
[3]	卢红霞, 郭燕军, 黄晗, 张婷. miR-421靶向MPP7/EGFR/AKT轴影响巨噬细胞M2极化改善哮喘小鼠的气道炎症[J]. 天津医药, 2026, 54(5): 462-468.
[4]	徐彤, 杨星旺, 刘永辉. Toll样受体激动剂及其在肿瘤疫苗中的应用研究进展[J]. 天津医药, 2026, 54(5): 550-555.
[5]	赵政委, 许文艳, 郭晓敏, 王敏, 李建丽, 李志海, 沈东琼, 涂云贵. 脓毒症患者血清LRG1、suPAR水平对并发急性肾损伤的预测价值[J]. 天津医药, 2026, 54(4): 374-378.
[6]	冯小艳, 张文倩, 方自红, 张广辉. NRP-1和CXCR4对卵巢子宫内膜异位囊肿患者妊娠结局的预测价值[J]. 天津医药, 2026, 54(4): 402-406.
[7]	姜天佑, 李敏, 孙碧文, 李越洋, 邢丽静, 田晨. Let-7b诱导白血病相关巨噬细胞复极抑制AML的发展[J]. 天津医药, 2026, 54(3): 225-231.
[8]	黄熷远, 付靖, 赵亚, 王龙灏, 仓顺东. 非小细胞肺癌EGFR-TKI耐药与p53基因突变的研究进展[J]. 天津医药, 2026, 54(3): 333-336.
[9]	万艳波, 刘明, 王勇. 秦皮甲素调节HMGB1/RAGE信号通路对缺氧/复氧诱导的心肌细胞损伤的影响[J]. 天津医药, 2025, 53(8): 796-801.
[10]	贾文歆, 周利娟, 王丽香. 血清CCL21、NLRP3与脑梗死患者机械取栓术后出血转化的相关性研究[J]. 天津医药, 2025, 53(7): 700-703.
[11]	吴素勤, 徐子舒, 许智晶, 吴洁, 王聪梅. 重症颅脑损伤减压术患者血清MMP-10、TLR2水平及其与疾病转归的关系[J]. 天津医药, 2025, 53(7): 704-708.
[12]	杜凌云, 王耀武, 任楠. 肾透明细胞癌中PRMT2、TRAF2与转移相关基因表达对预后的评估价值[J]. 天津医药, 2025, 53(5): 492-497.
[13]	邓海娟, 权永娟, 李芳. 妊娠期糖尿病患者血清GPER1、CFH水平与妊娠结局的关系[J]. 天津医药, 2025, 53(4): 369-373.
[14]	郑少阳, 智慧, 王曼, 武冰, 张清格, 李冠阳. 酒精性肝病患者外周血sTim-3、sST2水平与疾病严重程度的相关性[J]. 天津医药, 2025, 53(4): 383-388.
[15]	彭溪, 杨莉莉, 刘敏, 张峻梅. 肺部肺炎克雷伯菌感染患者血清SOCS-1、sTREM-2、ACLY变化及临床意义[J]. 天津医药, 2025, 53(4): 397-401.

组别	TGFBR1	细胞增殖活力（OD₄₅₀）
组别	TGFBR1	0 h	24 h	48 h	72 h
si-NC组	0.95±0.08	0.21±0.06	0.59±0.10	0.98±0.11	1.52±0.12
si-TGFB- R1组	0.41±0.12	0.22±0.05	0.45±0.06	0.73±0.13	0.95±0.13
t	6.485^＊	0.222	2.079	2.543	5.580^＊

组别	TGFBR1	细胞增殖活力（OD₄₅₀）
组别	TGFBR1	0 h	24 h	48 h	72 h
si-NC组	0.95±0.08	0.21±0.06	0.59±0.10	0.98±0.11	1.52±0.12
si-TGFB- R1组	0.41±0.12	0.22±0.05	0.45±0.06	0.73±0.13	0.95±0.13
t	6.485^＊	0.222	2.079	2.543	5.580^＊